Hebert Kathy, Arcement Lee, Horswell And Ron
Washington, DC 20001, USA.
Curr Heart Fail Rep. 2006 Jun;3(2):89-95. doi: 10.1007/s11897-006-0007-9.
beta-Blocker therapy has changed the landscape of treatment for chronic heart failure (HF). First recommended in published guidelines in 1999, the use of beta-blockers has become the cornerstone of therapy. beta-Blockers reduce both morbidity and mortality and also improve quality of life. This paper reviews and highlights the evidence supporting the current usage of beta-blockers in HF. It also shares practical, real world tricks-of-the-trade regarding such usage drawn from 8 years of experience with over 3000 patients in eight safety net hospitals. Each hospital mentioned in this paper participates in an HF disease management program serving the needs of Louisiana's indigent population.
β受体阻滞剂疗法改变了慢性心力衰竭(HF)的治疗格局。1999年β受体阻滞剂首次在已发表的指南中被推荐使用,现已成为治疗的基石。β受体阻滞剂可降低发病率和死亡率,还能提高生活质量。本文回顾并强调了支持目前β受体阻滞剂在HF治疗中应用的证据。同时,本文还分享了在八家安全网医院为3000多名患者治疗8年所积累的实际应用技巧。本文提及的每家医院都参与了一项HF疾病管理项目,以满足路易斯安那州贫困人口的需求。